Nilaya Varma, Group CEO & Co-Founder, Primus Partners, highlighted the strong healthcare demand in the US, driven by rising drug prices and a push for affordable care. He emphasized that the Affordable Care Act has boosted access, increasing demand for generics and biosimilars. Additionally, US efforts to diversify supply chains away from China are opening doors for Indian pharmaceutical firms, which are leveraging their generics experience and gaining global approvals through strategic partnerships.